Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells

Song,Hyun  Beom; Jun,Hyoung-Oh; Kim,Jin   Hyoung; Yu,Young  Suk; Kim,Kyu-Won; Min,Bon   Hong; Kim,Jeong  Hun

doi:10.3892/or.2013.2764

Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells

Authors:
- Hyun Beom Song
- Hyoung-Oh Jun
- Jin Hyoung Kim
- Young Suk Yu
- Kyu-Won Kim
- Bon Hong Min
- Jeong Hun Kim
View Affiliations

Affiliations: Fight against Angiogenesis-Related Blindness Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea, Department of Pharmacology, Seoul National University, Seoul, Republic of Korea, Department of Pharmacology, College of Medicine, Korea University, Seoul, Republic of Korea
Published online on: October 1, 2013 https://doi.org/10.3892/or.2013.2764
Pages: 2713-2718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clusterin is a cytoprotective chaperone protein that is known to protect various retinal cells. It was also reported to be overexpressed in several types of malignant tumors, whose chemoresistance correlates with the expression of clusterin. Herein, we investigated the effect of clusterin on cisplatin-induced cell death of retinoblastoma cells. Firstly, evaluation of clusterin expression demonstrated that it was highly expressed in human retinoblastoma tissues and cell lines (SNUOT-Rb1 and Y79) particularly in the area between viable cells around vessels and necrotic zones in the relatively avascular area in human retinoblastoma tissues. Furthermore, the effects of cisplatin on retinoblastoma cells were evaluated. Cisplatin (1 µg/ml) significantly affected cell viability of SNUOT-Rb1 cells by inducing caspase-3-dependent apoptosis. Notably, the cell death due to cisplatin was prevented by 5 µg/ml of clusterin administered 4 h prior to cisplatin treatment by inhibiting cisplatin-induced apoptosis. Furthermore, overexpression of clusterin exerted its anti-apoptotic effect on cisplatin-induced apoptosis, and effectively prevented cisplatin-induced cell death. These data suggest that clusterin, found to be expressed in human retinoblastoma, may exert anti-apoptotic effects on cisplatin-induced apoptosis and prevent cell death. Therefore, clusterin can contribute to cisplatin resistance of retinoblastoma.

View Figures

View References

1	Abramson DH: Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 46:2683–2691. 2005. View Article : Google Scholar : PubMed/NCBI
2	Kim JW, Abramson DH and Dunkel IJ: Current management strategies for intraocular retinoblastoma. Drugs. 67:2173–2185. 2007. View Article : Google Scholar : PubMed/NCBI
3	Gombos DS and Chevez-Barrios AP: Current treatment and management of retinoblastoma. Curr Oncol Rep. 9:453–458. 2007. View Article : Google Scholar
4	Varan A, Kiratli H, Aydin B, et al: The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr Hematol Oncol. 29:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kim H, Lee JW, Kang HJ, et al: Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience. Cancer Res Treat. 40:164–171. 2008. View Article : Google Scholar : PubMed/NCBI
6	Makimoto A: Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball. Int J Clin Oncol. 9:7–12. 2004. View Article : Google Scholar : PubMed/NCBI
7	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
8	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
9	Galluzzi L, Senovilla L, Vitale I, et al: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
10	Koberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
11	Shields CL, Mashayekhi A, Au AK, et al: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 113:2276–2280. 2006. View Article : Google Scholar : PubMed/NCBI
12	Ammar H and Closset JL: Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 283:12851–12861. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wyatt A, Yerbury J, Poon S, Dabbs R and Wilson M: Chapter 6: the chaperone action of clusterin and its putative role in quality control of extracellular protein folding. Adv Cancer Res. 104:89–114. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kim JH, Kim JH, Yu YS, Min BH and Kim KW: Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 51:1659–1665. 2010. View Article : Google Scholar : PubMed/NCBI
15	Kim JH, Kim JH, Jun HO, et al: Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 51:561–566. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ and Kim KW: Establishment and characterization of a novel, spontaneously immortalized retinoblastoma cell line with adherent growth. Int J Oncol. 31:585–592. 2007.PubMed/NCBI
17	Kim JH, Kim JH, Yu YS, Min BH and Kim KW: The role of clusterin in retinal development and free radical damage. Br J Ophthalmol. 91:1541–1546. 2007. View Article : Google Scholar : PubMed/NCBI
18	Yang GF, Li XM and Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
19	Watari H, Kanuma T, Ohta Y, et al: Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res. 16:345–352. 2010. View Article : Google Scholar
20	Kim JH, Yu YS, Kim KW and Min BH: The role of clusterin in in vitro ischemia of human retinal endothelial cells. Curr Eye Res. 32:693–698. 2007. View Article : Google Scholar : PubMed/NCBI
21	Burnier MN, McLean IW, Zimmerman LE and Rosenberg SH: Retinoblastoma. The relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci. 31:2037–2040. 1990.PubMed/NCBI
22	Lourda M, Trougakos IP and Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J. Int J Cancer. 120:611–622. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI
24	Trougakos IP, Lourda M, Antonelou MH, et al: Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res. 15:48–59. 2009. View Article : Google Scholar
25	Hara I, Miyake H, Gleave ME and Kamidono S: Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res. 92:1220–1224. 2001. View Article : Google Scholar
26	Miyake H, Hara I, Kamidono S and Gleave ME: Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res. 7:4245–4252. 2001.
27	Laskin JJ, Nicholas G, Lee C, et al: Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 7:579–586. 2012. View Article : Google Scholar : PubMed/NCBI
28	Saad F, Hotte S, North S, et al: Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 17:5765–5773. 2011. View Article : Google Scholar : PubMed/NCBI